Elio Mazzone

Elio Mazzone


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2021 in European Urology Oncology
Verified
Journal Article
Closed access
EMElio Mazzone
Elio Mazzone
ASArmando Stabile
Armando Stabile
FPFrancesco Pellegrino
Francesco Pellegrino
GBGiuseppe Basile
Giuseppe Basile
DCDaniele Cignoli
Daniele Cignoli
ABAlberto Briganti
Alberto Briganti

6 April 2020 in BJU International
Verified
Journal Article
Closed access
PDF file
SPStefano Puliatti
Stefano Puliatti
AEAhmed Eissa
Ahmed Eissa
RERadwa Eissa
Radwa Eissa
MAMarco Amato
Marco Amato
EMElio Mazzone
Elio Mazzone
BRBernardo Rocco
Bernardo Rocco

1 October 2020 in European Urology
Verified
Journal Article
Closed access
AMAlberto Martini
Alberto Martini
UFUgo Falagario
Ugo Falagario
AVArnauld Villers
Arnauld Villers
Paolo Dell'OglioPaolo Dell'Oglio
Paolo Dell'Oglio
EMElio Mazzone
Elio Mazzone
AHAshok K. Hemal
Ashok K. Hemal

1 March 2022 in Journal of Endourology
Verified
Journal Article
Closed access
RFRui Farinha
Rui Farinha
SPStefano Puliatti
Stefano Puliatti
EMElio Mazzone
Elio Mazzone
MAMarco Amato
Marco Amato
GRGiuseppe Rosiello
Giuseppe Rosiello
AMAlexandre Mottrie
Alexandre Mottrie
Purpose: To summarize the scientific published literature on new robotic surgical platforms with potential use in the urological field, reviewing their evolution from presentation until the present day. Our goal is to describe the current characteristics and possible prospects for these platforms. Materials and Methods: A nonsystematic search of the PubMed, Cochrane library's Central, EMBASE, MEDLINE, and Scopus databases was conducted to identify scientific literature about new robotic platforms other than the Da Vinci ® system, reviewing their evolution from inception until December 2020. Only English language publications were included. The following keywords were used: “new robotic platforms,” “Revo-I robot,” “Versius robot,” and “Senhance robot.” All relevant English-language original studies were analyzed by one author (R.F.) and summarized after discussion with an independent third party (E.M., S.Y., S.P., and M.A.). Results: Since 1995, Intuitive Surgical, Inc., with the Da Vinci surgical system, is the leading company in the robotic surgical market. However, Revo-I ® , Versius ® , and Senhance ® are the other three platforms that recently appeared on the market with available articles published in peer-reviewed journals. Among these three new surgical systems, the Senhance robot has the most substantial scientific proof of its capacity to perform minimally invasive urological surgery and as such, it might become a contender of the Da Vinci robot. Conclusions: The Da Vinci surgical platform has allowed the diffusion of robotic surgery worldwide and showed the different advantages of this type of technique. However, its use has some drawbacks, especially its price. New robotic platforms characterized by unique features are under development. Of note, they might be less expensive compared with the Da Vinci robotic system. We found that these new platforms are still at the beginning of their technical and scientific validation. However, the Senhance robot is in a more advanced stage, with clinical studies supporting its full implementation.

1 July 2019 in Journal of Urology
Verified
Journal Article
Closed access
CBCarlo Bravi
Carlo Bravi
ATAmy Tin
Amy Tin
EVEmily Vertosick
Emily Vertosick
EMElio Mazzone
Elio Mazzone
AMAlberto Martini
Alberto Martini
AVAndrew Vickers
Andrew Vickers
Purpose:Improved cancer control with increasing surgical experience (the learning curve) has been demonstrated for open and laparoscopic prostatectomy. We assessed the relationship between surgical...

29 November 2020 in BJU International
Verified
Journal Article
Open access
PDF file
AMAlexandre Mottrie
Alexandre Mottrie
EMElio Mazzone
Elio Mazzone
PWPeter Wiklund
Peter Wiklund
MGMarkus Graefen
Markus Graefen
Justin W. CollinsJustin W. Collins
Justin W. Collins
AGAnthony G. Gallagher
Anthony G. Gallagher
Objective: To develop and seek consensus from procedure experts on the metrics that best characterise a reference robot‐assisted radical prostatectomy (RARP) and determine if the metrics distinguished between the objectively assessed RARP performance of experienced and novice urologists, as identifying objective performance metrics for surgical training in robotic surgery is imperative for patient safety. Materials and methods: In Study 1, the metrics, i.e. 12 phases of the procedure, 81 steps, 245 errors and 110 critical errors for a reference RARP were developed and then presented to an international Delphi panel of 19 experienced urologists. In Study 2, 12 very experienced surgeons (VES) who had performed >500 RARPs and 12 novice urology surgeons performed a RARP, which was video recorded and assessed by two experienced urologists blinded as to subject and group. Percentage agreement between experienced urologists for the Delphi meeting and Mann–Whitney U ‐ and Kruskal–Wallis tests were used for construct validation of the newly identified RARP metrics. Results: At the Delphi panel, consensus was reached on the appropriateness of the metrics for a reference RARP. In Study 2, the results showed that the VES performed ~4% more procedure steps and made 72% fewer procedure errors than the novices ( P = 0.027). Phases VIIa and VIIb (i.e. neurovascular bundle dissection) best discriminated between the VES and novices. Limitations: VES whose performance was in the bottom half of their group demonstrated considerable error variability and made five‐times as many errors as the other half of the group ( P = 0.006). Conclusions: The international Delphi panel reached high‐level consensus on the RARP metrics that reliably distinguished between the objectively scored procedure performance of VES and novices. Reliable and valid performance metrics of RARP are imperative for effective and quality assured surgical training.